Innovent Biologics Inc., a leading biopharmaceutical company, has released its 2024 Environmental, Social and Governance $(ESG)$ Report, highlighting its commitment to sustainable development. Key areas of focus include governance, health, quality, people, and ecology. Innovent has received an MSCI ESG rating of AAA, making it the only biotech in China and one of three globally to achieve this distinction. The company emphasizes its dedication to bridging healthcare gaps through innovative therapies and enhancing drug accessibility and affordability. Innovent's ESG efforts also include supplier compliance and community support initiatives.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.